Document is current

Article History

Received: 25 July 2022

Accepted: 1 July 2024

First Online: 13 July 2024

Competing interests

: A.D.H. received speaker and consultancy honoraria from AstraZeneca, Amgen, Clovis, Daiichi Sankyo, Eisai, GenomicHealth, Gilead, GSK, Hexal, Lilly, MSD, Novartis, Pfizer, Roche, Pierre-Fabre and Seagen and travel support from AstraZeneca, Pfizer, Roche and Gilead. Ar.Ha. received honoraria from AstraZeneca, Cepheid, Merck Sharp & Dohme, Qiagen, Bristol-Myers Squibb, Illumina, Roche, Janssen, Lilly, Agilent, Diaceutics, Ipsen. F.A.T. received honoraria from AstraZeneca and GlaxoSmithKline. T.N.F. received honoraria from Roche, Novartis, Pfizer, AstraZeneca, Merck Sharp & Dohme, Teva, Daiichi Sankyo. E.C.P. received grants from Grail. H.-C.K. received honoraria and travel support from Carl Zeiss meditec, Theraclion, Novartis, Amgen, AstraZeneca, Pfizer, Roche, Daiichi Sankyo, Tesaro, MSD, onkowissen, Eli Lilly, SurgVision, Exact Sciences and Genomic Health and owns stock of Theraclion and Phaon scientific. P.H. received honoraria, unrestricted educational grants and research funding from Amgen, UCB, Novartis, and Pfizer. P.A.F. received honoraria from Novartis, Pfizer, Daiichi Sankyo, AstraZeneca, Eisai, clin-sol, onkowissen, Merck Sharp & Dohme, Lilly, PierreFabre, Seagen, Roche, Hexal and Agendia. His institution conducts research for Biontech and Cepheid. F.J.C. received honoraria from AstraZeneca, QIAGEN and Ambry Genetics. H.T. received honoraria from Novartis, Pfizer, Roche, Lilly, Seagen, and AstraZeneca. J.E. received honoraria from AstraZeneca Roche, Celgene, Novartis, Pfizer, Pierre Fabre, TEVA and travel support from AstraZeneca, Celgene, Pfizer, TEVA and Pierre Fabre. M.P.L. received honoraria from Pfizer, Roche, MSD, Novartis, AstraZeneca, Eisai, medac, Pierre Fabre, Grünenthal, PharmaMar, Exact Sciences and Lilly for advisory boards, lectures and travel support. M.W. received honoraria from AstraZeneca, Celgene and Novartis. D.L. received honoraria from Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Loreal, Pfizer, Pierre Fabre, Novartis, Roche and Teva. V.M. reports speaker honoraria from Amgen, Astra Zeneca, Daiichi Sankyo, Eisai, Pfizer, MSD, Novartis, Roche, Teva, Seagen, GSK, consultancy honoraria from Genomic Health, Gilead, Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi Sankyo, Eisai, Lilly, GSK, other from Novartis, Roche, Seagen, Genentech, outside the submitted work. E.B. received honoraria from Novartis, Pfizer, AstraZeneca, MSD, Lilly, Daiichi Sankyo, Roche and Hexal for consulting and clinical research management activities. D.W. received honoraria from Consal and research funding from Roche, Pfizer, Novartis, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo. A.S. reports grants from Celgene, grants from Roche, grants from AbbVie, personal fees from Roche, AstraZeneca, Celgene, Pfizer, Novartis, Merck Sharp & Dohme, Tesaro, Lilly, Seagen. S.Y.B. received honoraria from Roche Novartis, Pfizer, AstraZenca and Teva. M.U. received honoraria from Abbvie, Amgen, AstraZeneca, Bristol Myer Squibb, Celgene, Daiichi Sankyo, Eisai, Janssen Cilag, Johnson&Johnson, Lilly, Merck Sharp & Dohme, Mundipharma, Myriad Genetics, Odonate, Pfizer, Puma, Riemser, Roche, Sanofi Aventis, Sividon, and Teva. P.W. received honoraria from AstraZeneca, Merck Sharp & Dohme, Teva, Eisai, Novartis, Pfizer, Roche, Amgen, Pfizer, Tesaro, Pharmamar All remaining authors (L.H., R.D.G., M.R., W.J., S.U., H.H., Al.He., L.A.W., C.G., S.H., A.B.E, M.W.B., C.H., D.A.) have declared no conflicts of interest.